Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 3,000 shares of the stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $150.00, for a total transaction of $450,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Jazz Pharmaceuticals plc – (NASDAQ JAZZ) opened at $149.71 on Thursday. Jazz Pharmaceuticals plc – has a one year low of $117.16 and a one year high of $163.75. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63. The firm has a market cap of $8,980.00, a P/E ratio of 24.66, a PEG ratio of 0.80 and a beta of 0.97.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $2.93 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.40. Jazz Pharmaceuticals had a net margin of 23.58% and a return on equity of 22.92%. sell-side analysts anticipate that Jazz Pharmaceuticals plc – will post 9.76 earnings per share for the current year.
A number of equities research analysts have issued reports on JAZZ shares. BMO Capital Markets reiterated a “buy” rating and set a $196.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, September 20th. UBS Group reiterated a “buy” rating and set a $172.00 price objective (down from $175.00) on shares of Jazz Pharmaceuticals in a research note on Monday, September 25th. Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $165.00 price objective on the stock. Morgan Stanley started coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, October 5th. They set an “equal weight” rating and a $155.00 price objective on the stock. Finally, FBR & Co started coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $206.00 price objective on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company. Jazz Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $181.48.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.